

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 January 2003 (09.01.2003)

PCT

(10) International Publication Number
WO 03/002556 A1

(51) International Patent Classification⁷: C07D 405/12,
413/12, A61K 31/497, 31/536 [SE/DK]; Hornemansgade 23, DK-2100 København Ø (DK).

(21) International Application Number: PCT/DK02/00435

(22) International Filing Date: 27 June 2002 (27.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2001 01036 29 June 2001 (29.06.2001) DK

(71) Applicant (for all designated States except US): H. LUNDBECK A/S [DK/DK]; Ottiliaevej 9, DK-2500 Valby-Copenhagen (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROTTLÄNDER, Mario [DE/DK]; Harrestrupvang 3C, 2th, DK-2500 Valby (DK). MOLTZEN, Ejner, Knud [DK/DK]; Toftekærsvæj 29, DK-2820 Gentofte (DK). MIKKELSEN, Ivan [DK/DK]; Strandvejen 97, DK-4600 Køge (DK). RUHLAND, Thomas [DE/DK]; Østergaards Alle 16, DK-2500 Valby (DK). ANDERSEN, Kim [DK/DK]; Ringerbakken 22, DK-2830 Virum (DK). KROG-JENSEN, Christian

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EB, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE



(57) Abstract: A heteroaryl derivative having the formula (I). The compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and neurological disorders such as psychosis.

Novel heteroaryl derivatives, their preparation and use

The present invention relates to novel heteroaryl derivatives potently binding to the 5-HT_{1A} receptor, pharmaceutical compositions containing these compounds and the use thereof for the treatment of certain psychiatric and neurological disorders. Many of the compounds of the invention have also potent serotonin reuptake inhibition activity and are thus considered particularly useful for the treatment of depression.

Furthermore, many compounds of the invention have also effect at dopamine D₃ and D₄ receptors and are considered to be useful for the treatment of psychosis.

Background Art

Clinical and pharmacological studies have shown that 5-HT_{1A} agonists and partial agonists are useful in the treatment of a range of affective disorders such as generalised anxiety disorder, panic disorder, obsessive compulsive disorder, depression and aggression.

It has also been reported that 5-HT_{1A} ligands may be useful in the treatment of ischaemia.

An overview of 5-HT_{1A} antagonists and proposed potential therapeutic targets for these antagonists based upon preclinical and clinical data are presented by Schechter et al., *Serotonin* 1997, Vol.2, Issue 7. It is stated that 5-HT_{1A} antagonists may be useful in the treatment of schizophrenia, senile dementia, dementia associated with Alzheimer's disease, and in combination with SSRI antidepressants also to be useful in the treatment of depression.

5-HT reuptake inhibitors are well-known antidepressant drugs and useful for the treatment of panic disorders and social phobia.

The effect of combined administration of a compound that inhibits serotonin reuptake and a 5-HT_{1A} receptor antagonist has been evaluated in several studies (Innis, R.B. et al. *Eur. J. Pharmacol.* 1987, 143, p 195-204 and Gartside, S.E., *Br. J. Pharmacol.* 1995, 115, p 1064-1070, Blier, P. et al. *Trends Pharmacol. Sci.* 1994, 15, 220). In these studies it was found

that combined 5-HT_{1A} receptor antagonists and serotonin reuptake inhibitors would produce a more rapid onset of therapeutic action.

Dopamine D₄ receptors belong to the family of dopamine D₂-like receptors which is

5 considered to be responsible for the antipsychotic effects of neuroleptics. Dopamine D₄ receptors are primarily located in areas of the brain other than *striatum*, suggesting that dopamine D₄ receptor ligands have antipsychotic effect and are devoid of extrapyramidal activity.

10 Accordingly, dopamine D₄ receptor ligands are potential drugs for the treatment of psychosis and positive symptoms of schizophrenia and compounds with combined effects at dopamine D₄, and serotonergic receptors may have the further benefit of improved effect on negative symptoms of schizophrenia, such as anxiety and depression, alcohol abuse, impulse control disorders, aggression, side effects induced by conventional antipsychotic

15 agents, ischaemic disease states, migraine, senile dementia and cardiovascular disorders and in the improvement of sleep.

Dopamine D₃ receptors also belong to the family of dopamine D₂ like receptors. D₃ antagonistic properties of an antipsychotic drug could reduce the negative symptoms and

20 cognitive deficits and result in an improved side effect profile with respect to EPS and hormonal changes.

Accordingly, agents acting on the 5-HT_{1A} receptor, both agonists and antagonists, are

believed to be of potential use in the therapy of psychiatric and neurological disorders and

25 thus being highly desired. Furthermore, antagonists at the same time having potent serotonin reuptake inhibition activity and/or D₄ and/or D₃ activity may be particularly useful for the treatment of various psychiatric and neurological diseases.


Bart J van Steen et al. *J. Med. Chem.* 1994, 37(17), 2761-73 describes certain related

30 benzofuran and benzodioxan derivatives having affinity for the 5-HT_{1A} receptor and therefore being useful in the treatment of depression and anxiety.

Summary of the Invention

It has now been found that compounds of a certain class of heteroaryl derivatives bind to the 5-HT_{1A} receptor with high affinities. Additionally, the compounds also show serotonin 5 reuptake inhibition activity. Furthermore, it has been found that many of the compounds have effect at dopamine D₃ and/or D₄ receptors.

Accordingly, the present invention relates to novel compounds of the general Formula I:



wherein

X represents O, NR¹⁶, S or CR⁴R⁵.

15 Y is $-\text{CR}^6\text{R}^7-$, $-\text{CR}^6\text{R}^7-\text{CR}^8\text{R}^9-$, $-\text{CR}^6=\text{CR}^7-$ or $\text{CO}-\text{CR}^6\text{R}^7$; or

X and Y together form a group $-\text{CR}^4=\text{CR}^5-$ or $-\text{CR}^4=\text{CR}^5-\text{CR}^6\text{R}^7-$;

2

n is 2, 3, 4, 5, 6, 7, 8, 9 or 10:

20 m is 2 or 3;

A is O or S;

W is N, C or CH

Q is N, C or CH;

in the dotted line m

trifluoromethyl, trifluoromethoxy, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, aryl-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, hydroxy, formyl, acyl, amino, C₁₋₆-alkylamino, di(C₁₋₆-alkyl)amino, acylamino, C₁₋₆-alkoxycarbonylamino,

aminocarbonylamino, C₁₋₆-alkylaminocarbonylamino and di(C₁₋₆-alkyl)aminocarbonylamino; and

R¹⁶ is selected from hydrogen, halogen, nitro, cyano, trifluoromethyl, C₁₋₆-alkyl, C₂₋₆-

5 alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, aryl-C₁₋₆-alkyl, formyl, acyl; and

R¹⁰ and R¹¹ are each independently selected from hydrogen and C₁₋₆-alkyl or may together form a bridge consisting of two or three methylene groups; and

10 R¹², R¹³, R¹⁴ and R¹⁵ are each independently selected from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, aryl, heteroaryl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₁₋₆-alkylsulphonyl, hydroxy, formyl, acyl, amino, acylamino, aminocarbonyl, C₁₋₆-alkoxycarbonylamino, aminocarbonylamino, C₁₋₆-alkylaminocarbonylamino, di(C₁₋₆-alkyl)aminocarbonylamino,

15 SO₂NR²⁰R²¹ and NR²⁰R²¹ wherein R²⁰ and R²¹ independently represent hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl; or R²⁰ and R²¹ together with the nitrogen to which they are attached form a 5- or 6-membered ring optionally containing one further heteroatom, which ring may optionally be substituted by C₁₋₆-alkyl or acyl;

20 any of its enantiomers or any mixture thereof, or an acid addition salt thereof.

The invention also relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier or diluent.

25

In a further embodiment, the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of a disorder or disease responsive to the inhibition of serotonin uptake and antagonism of 5-HT_{1A} receptors.

30

In a further embodiment, the invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament

for the treatment of a disorder or disease responsive to the combined effect of 5-HT_{1A} receptors and dopamine D₄ receptors.

In particular, the invention relates to the use of a compound according to the invention or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders; other psychiatric disorders such as psychosis and neurological disorders.

10 In still another embodiment, the present invention relates to a method for the treatment of a disorder or disease of living animal body, including a human, which is responsive to the inhibition of serotonin uptake and antagonism of 5-HT_{1A} receptors comprising administering to such a living animal body, including a human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.

15

In still another embodiment, the present invention relates to a method for the treatment of a disorder or disease of living animal body, including a human, which is responsive to the effect of 5-HT_{1A} and D₄ receptors comprising administering to such a living animal body, including a human, a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.

20 Due to their combined antagonism of 5-HT_{1A} receptors and serotonin reuptake inhibiting effect, the compounds of the invention are considered particularly useful as fast onset of action medicaments for the treatment of depression. The compounds may also be useful for the treatment of depression in patients who are resistant to treatment with currently available antidepressants.

25 The compounds of the invention have high affinity for the 5-HT_{1A} and D₄ receptors.

30 Accordingly, the compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders; other psychiatric disorders such as psychosis and neurological disorders.

Detailed Description of the Invention

In preferred embodiments of the invention, Z is O.

In preferred embodiments of the invention, Y is $-\text{CH}_2\text{CH}_2-$ or $-\text{CH}_2\text{CO}-$.

5 In preferred embodiments of the invention, X is O or NH.

In preferred embodiments of the invention, W is N.

In preferred embodiments of the invention, m is 2.

In a further embodiment of the invention, n is 2, 3 or 4.

In a more preferred embodiment of the invention, n is 2.

10

In preferred embodiments of the invention, R^1 , R^2 and R^3 independently represent hydrogen, halogen or CN.

15 In a further embodiment of the invention, R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are independently selected from a group consisting of hydrogen, heteroaryl, trifluoromethyl, cyano, C_{1-6} -alkyl, halogen, $\text{NR}^{20}\text{R}^{21}$, $\text{SO}_2\text{NR}^{20}\text{R}^{21}$, aryl, C_{1-6} -alkylsulfonyl and carbonylamino.

20 In a preferred embodiment of the invention, R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are independently selected from hydrogen, thiophen, trifluoromethyl, cyano, methyl, ethyl, cyclopropyl, chloro, bromo, fluoro, piperazine, 1-piperazine-4-methyl, 1-piperidine, 1-piperidinyl-sulfonyl, methanesulfonyl, methylsulfid, phenyl and carbonylamino.

Specific compounds of the invention are compounds selected from:

25 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinonitrile, 1a
2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methyl-4-trifluoromethylnicotinonitrile, 1b
2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methyl-4-trifluoromethylnicotinonitrile, 1c
30 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-(thiophen-2-yl)-4-trifluoromethylnicotinonitrile, 1d
{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinonitrile, 1e

3-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-2-methylpyridine, 1f
2-Chloro-3-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1g
2-Bromo-3-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1h
3-Chloro-5-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1i
5 2-Chloro-3-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1j
2-Bromo-3-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1k
3-Chloro-5-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1l
10 10 3-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-2-methylpyridine, 1m
4-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-(piperidin-1-ylsulfonyl)pyridine, 1n
15 4-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-(piperidin-1-ylsulfonyl)pyridine, 1o
2-{4-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, 1p
2-{4-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, 1q
20 2-{4-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, 1r
2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-5-trifluoromethylpyridine, 1s
25 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-4,6-dimethylnicotinonitrile, 1t
2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-4,6-dimethylnicotinonitrile, 1u
2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-5-trifluoromethylpyridine, 1v
30 2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-4,6-dimethylnicotinonitrile, 1x
2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2a

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-methanesulfonyl-4-methyl-6-phenylpyridine, 2b

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methyl-6-(piperidin-1-yl)nicotinonitrile, 2c

5 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinamide, 2d

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2e

4-Cyano-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 2f

10 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-6-methylnicotinamide, 2g

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy)-4-methyl-6-(piperidin-1-yl)nicotinonitrile, 2h

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy)-4-methyl-6-(4-methylpiperazin-1-yl)nicotinonitrile, 2i

15 6-Cyclopropyl-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy)-4-trifluoromethylnicotinonitrile, 2j

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-3-methanesulfonyl-4-methyl-6-phenylpyridine, 2k

20 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethyl-3-phenylsulfonylpyridine, 2l

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyridine, 2m

25 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylnicotinonitrile, 2n

6-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methylnicotinonitrile, 2o

5-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2p

30 6-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2q

6-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2r

2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylnicotinonitrile, 2s

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methylnicotinonitrile, 2t

5-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylnicotinonitrile, 2u

5-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2v

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2x

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2y

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2z

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2aa

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4-methylnicotinonitrile, 2ab

4-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, 2ac

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2ad

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2ae

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2af

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-5-fluoronicotinonitrile, 2ag

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2ah

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2ai

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4-methylnicotinonitrile, 2aj

4-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, 2ak

5 5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2al

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2am

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2an

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-5-fluoronicotinonitrile, 2ao

5-Cyano-4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyrimidine, 2ap

15 5-Cyano-4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylsulfanyl-2-phenylpyrimidine, 2aq

5-Cyano-4-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyrimidine, 2ar

5-Cyano-4-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-

20 6-methylsulfanyl-2-phenylpyrimidine, 2as

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylpyrimidine, 2at

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylpyrimidine, 2au

25 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methoxynicotinonitrile, 2av

6-Chloro-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2ax

6-Chloro-2-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-

30 5-fluoronicotinonitrile, 2ay

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-ethylpyrimidine, 2az

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-trifluoromethylpyrimidine, 2ba

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethoxypyrimidine, 2bb

5 4-Chloro-2-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylpyrimidine, 2bc

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-trifluoromethylpyrimidine, 2bd

10 Some of the compounds of general Formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention.

The term C₁₋₆ alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl and 2-methyl-1-propyl.

Similarly, C₂₋₆ alkenyl and C₂₋₆ alkynyl, respectively, designate such groups having from two to six carbon atoms inclusive.

20 Halogen means fluoro, chloro, bromo or iodo.

The term C₃₋₈ cycloalkyl designates a monocyclic or bicyclic carbocycle having three to eight C-atoms, such as cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

25 The terms C₁₋₆ alkoxy, C₁₋₆ alkylthio and C₁₋₆ alkylsulphonyl designate such groups in which the alkyl group is C₁₋₆ alkyl as defined above.

The term aryl designates an aromatic hydrocarbon such as phenyl or naphtyl.

30 The term heteroaryl refers to a mono- or bicyclic heterocyclic aromatic group containing at least one N, S or O atom, such as furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyridyl, pyrimidyl, tetrazolyl, benzofuranyl, benzothienyl,

benzimidazolyl, indolyl. Preferred heteroaryls are monocyclic aryls. Especially preferred are thienyl and piperidinyl.

Acyl means -CO-alkyl wherein the alkyl group is C₁₋₆ alkyl as defined above.

5 Amino means NH₂.

C₁₋₆ alkylamino means -NH-alkyl and di(C₁₋₆-alkyl)amino means -N-(alkyl)₂ where the alkyl group is C₁₋₆ alkyl as defined above.

10 Acylamino means -NH-acyl wherein acyl is as defined above.

Carbonylamino means -CONH-

15 C₁₋₆ alkoxy carbonylamino means alkyl-O-CO-NH- wherein the alkyl group is C₁₋₆ alkyl as defined above.

C₁₋₆ alkylaminocarbonylamino means alkyl-NH-CO-NH- wherein the alkyl group is C₁₋₆ alkyl as defined above.

20 di(C₁₋₆-alkyl)aminocarbonylamino means (alkyl)₂-N-CO-NH- wherein the alkyl group is C₁₋₆ alkyl as defined above.

25 As used herein, a phenyl group which may be substituted means a phenyl group which may be substituted one or more times with a substituent selected from halogen, trifluoromethyl, cyano, nitro, amino, C₁₋₆-alkylamino, di(C₁₋₆-alkyl)amino, C₁₋₆-alkyl, C₁₋₆-alkoxy and hydroxy.

Exemplary of organic acid addition salts according to the invention are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, 30 ethanesulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline. Exemplary of inorganic acid addition salts according to the invention are those with hydrochloric, hydrobromic, sulfuric,

sulfamic, phosphoric, and nitric acids. The acid addition salts of the invention are preferably pharmaceutically acceptable salts formed with non-toxic acids.

Furthermore, the compounds of this invention may exist in unsolvated as well as in solvated 5 forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.

Some of the compounds of the present invention contain chiral centres and such compounds 10 exist in the form of isomers (e.g. enantiomers). The invention includes all such isomers and any mixtures thereof including racemic mixtures.

Racemic forms can be resolved into the optical antipodes by known methods, for example, by separation of diastereomeric salts thereof with an optically active acid, and liberating the 15 optically active amine compound by treatment with a base. Another method for resolving racemates into the optical antipodes is based upon chromatography on an optically active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of d- or l- (tartrates, mandelates or camphorsulphonate) salts for example. The compounds of the present invention may also be 20 resolved by the formation of diastereomeric derivatives.

Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A. Collet and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981).

25



Optically active compounds can also be prepared from optically active starting materials.

The compounds of the invention can be prepared by one of the following methods comprising:

30

a) treating a compound of formula (II) with a compound of formula (III) in the presence of a reducing agent.

14





(II)

wherein n, m, R¹ - R³, R¹⁰, R¹¹, R¹² - R¹⁵, Q, W, X, Y, Z, A and the dotted line are as defined above;

b) treating a compound of formula (IV) with a compound of formula (V) in the presence of an appropriate base

10



wherein L is a suitable leaving group such as e.g. chloro and n, m, R¹ - R³, R¹⁰, R¹¹, R¹² - R¹⁵, Q, W, X, Y, Z, A and the dotted line are as defined above;

Whereupon the compounds of formula (I) are isolated as the free base or in the form of a pharmaceutically acceptable salt thereof.

The reductive amination according to method a) is preferably carried out in an inert organic solvent such as dimethylformamide or tetrahydrofuran in the presence of a reducing agent, eg triacetoxyborohydride, at room temperature.

- 5 The arylation according to method b) is conveniently performed in an inert organic solvent such as dimethylformamide in the presence of a base (eg potassium tert-butoxide) at a temperature in the range of 40-100 °C, preferably in the range of 40-80 °C, and most preferred around 50 °C.
- 10 Arylpiperazine derivatives of formula (II) are either commercially available or conveniently prepared from the corresponding arylamine according to the method described by Martin et al. *J. Med. Chem.* 1989, 32, 1052, or the method described by Kruse et al. *Rec. Trav. Chim. Pays-Bas* 1988, 107, 303. The starting arylamines are either commercially available or are well-described in the literature.
- 15 Aryltetrahydropyridine derivatives of formula (II) are known from literature, cf. US Pat. No. 2,891,066; McElvain et al. *J. Amer. Chem. Soc.* 1959, 72, 3134. Conveniently, the corresponding arylbromide is lithiated with BuLi followed by addition of 1-benzyl-4-piperidone. Subsequent treatment with acid gives the N-benzyl-aryltetrahydropyridine. The 20 benzyl group can be removed by catalytic hydrogenation or by treatment with e.g. ethyl chloroformate to give the corresponding ethyl carbamate followed by acidic or alkaline hydrolysis. The starting arylbromides are either commercially available or well-described in the literature.
- 25 Aldehydes of formula (III) are prepared as described in the Examples below. The starting chloropyridines are commercially available or made by methods well-described in the literature

The following examples will illustrate the invention further. They are, however, not to be 30 construed as limiting.

Examples

Melting points were determined on a Büchi SMP-20 apparatus and are uncorrected. Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with 5 IonSpray source (method D) or heated nebulizer (APCI, methods A and B) and Shimadzu LC-8A/SLC-10A LC system. The LC conditions [30 X 4.6 mm YMC ODS-A with 3.5 μ m particle size] were linear gradient elution with water/acetonitrile/trifluoroacetic acid (90:10:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 4 min at 2 mL/min. Purity was determined by integration of the UV trace (254 nm). The retention times R_t are 10 expressed in minutes.

Mass spectra were obtained by an alternating scan method to give molecular weight information. The molecular ion, MH^+ , was obtained at low orifice voltage (5-20V) and fragmentation at high orifice voltage (100V).

Preparative LC-MS-separation was performed on the same instrument. The LC conditions 15 (50 X 20 mm YMC ODS-A with 5 μ m particle size) were linear gradient elution with water/acetonitrile/trifluoroacetic acid (80:20:0.05) to water/acetonitrile/trifluoroacetic acid (10:90:0.03) in 7 min at 22.7 mL/min. Fraction collection was performed by split-flow MS detection.

1H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or 20 at 250.13 MHz on a Bruker AC 250 instrument. Deuterated chloroform (99.8%D) or dimethyl sulfoxide (99.9%D) were used as solvents. TMS was used as internal reference standard. Chemical shift values are expressed in ppm-values. The following abbreviations are used for multiplicity of NMR signals: s=singlet, d=doublet, t=triplet, q=quartet, 25 qui=quintet, h=heptet, dd=double doublet, dt=double triplet, dq=double quartet, tt=triplet of triplets, m=multiplet, b=broad singlet. NMR signals corresponding to acidic protons are generally omitted. Content of water in crystalline compounds was determined by Karl Fischer titration. Standard workup procedures refer to extraction with the indicated organic solvent from proper aqueous solutions, drying of combined organic extracts (anhydrous $MgSO_4$ or Na_2SO_4), filtering and evaporation of the solvent *in vacuo*. For column 30 chromatography silica gel of type Kieselgel 60, 230-400 mesh ASTM was used. For ion-exchange chromatography (SCX, 1 g, Varian Mega Bond Elut®, Chrompack cat. no. 220776). Prior use the SCX-columns were pre-conditioned with 10% solution of acetic acid in methanol (3 mL).

Example 14,6-Dimethyl-2-(2-oxoethylsulfanyl)nicotinonitrile.

4,6-Dimethyl-2-mercaptopnicotinonitrile (3.0 g) was dissolved in DMF (40 mL) and a
5 solution of potassium *tert*-butoxide (19.2 mL; 1 M) in *tert*-butanol added. The mixture was
stirred for 10 min, added dropwise to a solution of bromoacetaldehyd dimethylacetal (3.2 g)
in DMF (10 ml) and stirred over night at 70 °C. The mixture was poured on water and
extracted with ethyl acetate, the combined organic phases dried and evaporated to give an
oil (5.3 g) which was dissolved in dioxane (40 mL). HCl (20 mL; 3 M) was added and the
10 mixture was stirred at 30 °C for 2 h. NaHCO₃ was added until pH reached 5-6, the mixture
was extracted with ethyl acetate, the combined organic phases dried with Na₂SO₄ and
evaporated to give the title compound as an oil (2.9 g). ¹H NMR (CDCl₃) : δ 2.45 (s, 6H);
3.35 (d, 2H); 6.85 (s, 1H); 9.55 (t, 1H).

15 2-[2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, 1a.

4,6-Dimethyl-2-(2-oxo-ethylsulfanyl)nicotinonitrile (2.9 g) was dissolved in 1,2-dichloroethane (150 mL), a solution of 4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazine (2.6 g) in DMF (150 mL) was added, followed by addition of sodium triacetoxyborohydride
20 (14.9 g) and stirring for 2 h. The mixture was poured on water and Na₂CO₃ added until pH reached 7-8. The mixture was extracted with ethyl acetate, the combined organic phases dried and evaporated to give an oil which was subjected to purification by column chromatography (silica gel; ethyl acetate and heptane) giving an oil which precipitated as the oxalate salt (0.36 g) from acetone. LC/MS (m/z) 397 (MH⁺), RT = 1.91, purity: 97%.

25

The following compounds were prepared analogously:

2-[2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-6-methyl-4-trifluoromethylnicotinonitrile, 1b: LC/MS (m/z) 465 (MH⁺), RT = 2.17, purity: 73%.

30

2-[2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-6-methyl-4-trifluoromethylnicotinonitrile, 1c: LC/MS (m/z) 490 (MH⁺), RT = 2.21, purity: 82%.

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-(thiophen-2-yl)-4-trifluoromethylnicotinonitrile, **1d**: LC/MS (m/z) 533 (MH⁺), RT = 2.38, purity: 86%.

5 {2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinonitrile, **1e**: LC/MS (m/z) 422 (MH⁺), RT = 1.95, purity: 98%.

3-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-2-methylpyridine, **1f**: LC/MS (m/z) 356 (MH⁺), RT = 1.04, purity: 97%.

10 2-Chloro-3-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, **1g**: LC/MS (m/z) 376 (MH⁺), RT = 1.54, purity: 95%.

15 2-Bromo-3-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, **1h**: LC/MS (m/z) 422 (MH⁺), RT = 1.63, purity: 90%.

3-Chloro-5-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, **1i**: LC/MS (m/z) 376 (MH⁺), RT = 1.54, purity: 95%.

20 2-Chloro-3-{2-[4-(8-cyano-2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, **1j**: LC/MS (m/z) 401 (MH⁺), RT = 1.54, purity: 94%.

25 2-Bromo-3-{2-[4-(8-Cyano-2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, **1k**: LC/MS (m/z) 445 (MH⁺), RT = 1.63, purity: 92%.

30 3-Chloro-5-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, **1l**: LC/MS (m/z) 401 (MH⁺), RT = 1.59, purity: 90%.

3-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-2-methylpyridine, **1m**: LC/MS (m/z) 381 (MH⁺), RT = 1.08, purity: 100%.

4-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-(piperidin-1-ylsulfonyl)pyridine, **1n**: LC/MS (m/z) 530 (MH⁺), purity: 88%.

4-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-(piperidin-1-ylsulfonyl)pyridine, **1o**: LC/MS (m/z) 505 (MH⁺), RT = 1.87, purity: 100%.

5 2-{4-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, **1p**: LC/MS (m/z) 454 (MH⁺), RT = 2.14, purity: 75%.

2-{4-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, **1q**: LC/MS (m/z) 479 (MH⁺), RT = 2.14, purity: 82%.

10 2-{4-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, **1r**: LC/MS (m/z) 464 (MH⁺), RT = 2.08, purity: 71%.

15 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-5-trifluoromethylpyridine, **1s**: LC/MS (m/z) 440 (MH⁺), RT = 2.07, purity: 98%.

2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-4,6-dimethyl-nicotinonitrile, **1t**: LC/MS (m/z) 425 (MH⁺), RT = 1.99, purity: 100%.

20 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-4,6-dimethyl-nicotinonitrile, **1u**: LC/MS (m/z) 439 (MH⁺), RT = 2.05, purity: 82%.

2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-5-trifluoromethylpyridine, **1v**: LC/MS (m/z) 465 (MH⁺), RT = 2.07, purity: 97%.

25 2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-4,6-dimethylnicotinonitrile, **1x**: LC/MS (m/z) 450 (MH⁺), RT = 2.00, purity: 98%.

Example 2

30 2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylmercaptane. 1-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazine (4.5 g) and thiirane (1.75 g) were dissolved in DMF (200 mL) and refluxed for 1 h. The mixture was evaporated and re-dissolved in THF, dried with MgSO₄, filtered and evaporated to give an oil which was subjected to

purification by column chromatography (silica gel; ethyl acetate and heptane) giving the title compound as an oil (2.2 g). MS m/z (%): 261 (MH+, 100%), 202 (100%), 159 (23%).

2-[2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2a.

5 2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylmercaptane (2.2 g) was dissolved in a solution of potassium *tert*-butoxide (0.81 g) in DMF (25 ml), stirred for 15 min and heated to 50 °C. A solution of 2-chloronicotinonitrile (1.91 g) in DMF (25 mL) was added dropwise and stirring was continued for another 2 h at 50 °C. The mixture was evaporated and re-dissolved in THF, washed with brine, dried with MgSO₄, filtered and 10 evaporated to give an oil which was subjected to purification by column chromatography (silica gel; ethyl acetate, heptane and triethyl amine) giving the title compound as an oil which precipitated as the oxalate salt from acetone. (1.45 g). LC/MS (m/z) 383 (MH+), RT = 1.70, purity: 87%.

15. The following compounds were prepared analogously:

2-[2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-3-methanesulfonyl-4-methyl-6-phenylpyridine, 2b: LC/MS (m/z) 551 (MH+), RT = 2.20, purity: 77%.

20 *2-[2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-4-methyl-6-(piperidin-1-yl)nicotinonitrile, 2c: LC/MS (m/z) 505 (MH+), RT = 2.33, purity: 87%.*

25 *2-[2-[4-(8-Cyano-2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinamide, 2d: LC/MS (m/z) 440 (MH+), RT = 1.58, purity: 90%.*

2-[2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2e: LC/MS (m/z) 408 (MH+), RT = 1.75, purity: 96%.

30 *4-Cyano-2-[2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 2f: LC/MS (m/z) 367 (MH+), RT = 1.62, purity: 82%.*

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-6-methylnicotinamide,
2g: LC/MS (m/z) 399 (MH⁺), RT = 1.55, purity: 97%.

5 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-4-methyl-6-(piperidin-1-yl)nicotinonitrile, 2h: LC/MS (m/z) 464 (MH⁺), RT = 2.24, purity: 98%.

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-4-methyl-6-(4-methylpiperazin-1-yl)nicotinonitrile, 2i: LC/MS (m/z) 479 (MH⁺), RT = 1.34, purity: 79%.

10 6-Cyclopropyl-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-4-trifluoromethylnicotinonitrile, 2j: LC/MS (m/z) 475 (MH⁺), RT = 2.29, purity: 99%.

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-3-methanesulfonyl-4-methyl-6-phenylpyridine, 2k: LC/MS (m/z) 510 (MH⁺), RT = 2.16, purity: 98%.

15 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethyl-3-phenylsulfonylpyridine, 2l: LC/MS (m/z) 526 (MH⁺), RT = 2.11, purity: 92%.

20 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyridine, 2m: LC/MS (m/z) 383 (MH⁺), RT = 1.67, purity: 87%.

2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylnicotinonitrile, 2n: LC/MS (m/z) 412 (MH⁺), RT = 2.02, purity: 96%.

25 6-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methylnicotinonitrile, 2o: LC/MS (m/z) 432 (MH⁺), RT = 2.00, purity: 93%.

30 5-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2p: LC/MS (m/z) 418 (MH⁺), RT = 1.90, purity: 73%.

6-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2q: LC/MS (m/z) 418 (MH⁺), RT = 1.91, purity: 72%.

6-Chloro-2-{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2r: LC/MS (m/z) 436 (MH⁺), RT = 1.95, purity: 89%.

5 2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylnicotinonitrile, 2s: LC/MS (m/z) 436 (MH⁺), RT = 2.04, purity: 78%.

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methylnicotinonitrile, 2t: LC/MS (m/z) 457 (MH⁺), RT = 2.04, purity: 87%.

10 5-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylnicotinonitrile, 2u: LC/MS (m/z) 471 (MH⁺), RT = 2.24, purity: 81%.

15 5-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2v: LC/MS (m/z) 443 (MH⁺), RT = 1.97, purity: 81%.

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2x: LC/MS (m/z) 443 (MH⁺), RT = 1.91 purity: 87%.

20 6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2y: LC/MS (m/z) 461 (MH⁺), RT = 1.62, purity: 84%.

25 2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2z: LC/MS (m/z) 431 (MH⁺), RT = 1.62, purity: 94%.

30 2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2aa: LC/MS (m/z) 459 (MH⁺), RT = 1.87, purity: 72%.

30 6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4-methylnicotinonitrile, 2ab: LC/MS (m/z) 479 (MH⁺), RT = 1.91, purity: 97%.

4-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, **2ac**: LC/MS (m/z) 479 (MH⁺), RT = 1.87, purity: 85%.

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, **2ad**: LC/MS (m/z) 493 (MH⁺), RT = 2.12, purity: 98%.

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, **2ae**: LC/MS (m/z) 465 (MH⁺), RT = 1.87, purity: 96%.

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, **2af**: LC/MS (m/z) 465 (MH⁺), RT = 1.79, purity: 98%.

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-5-fluoronicotinonitrile, **2ag**: LC/MS (m/z) 483 (MH⁺), RT = 1.83, purity: 96%.

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, **2ah**: LC/MS (m/z) 417 (MH⁺), RT = 1.75, purity: 93%.

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, **2ai**: LC/MS (m/z) 445 (MH⁺), RT = 2.04, purity: 96%.

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4-methylnicotinonitrile, **2aj**: LC/MS (m/z) 465 (MH⁺), RT = 2.08, purity: 96%.

4-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, **2ak**: LC/MS (m/z) 465 (MH⁺), RT = 1.95, purity: 89%.

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, **2al**: LC/MS (m/z) 479 (MH⁺), RT = 2.24, purity: 97%.

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2am: LC/MS (m/z) 451 (MH⁺), RT = 2.00, purity: 96%.

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2an: LC/MS (m/z) 451 (MH⁺), RT = 1.95, purity: 74%.

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-5-fluoronicotinonitrile, 2ao: LC/MS (m/z) 469 (MH⁺), RT = 2.00, purity: 96%.

10 5-Cyano-4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyrimidine, 2ap: LC/MS (m/z) 384 (MH⁺), RT = 1.66, purity: 99%.

5-Cyano-4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylsulfanyl-2-phenylpyrimidine, 2aq: LC/MS (m/z) 507 (MH⁺), RT = 2.49, purity: 93%.

15 5-Cyano-4-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyrimidine, 2ar: LC/MS (m/z) 409 (MH⁺), RT = 1.70, purity: 98%.

5-Cyano-4-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylsulfanyl-2-phenylpyrimidine, 2as: LC/MS (m/z) 532 (MH⁺), RT = 2.49, purity: 91%.

25 2-[2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylpyrimidine, 2at: LC/MS (m/z) 387 (MH⁺), RT = 1.66, purity: 95%.

2-[2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylpyrimidine, 2au: LC/MS (m/z) 413 (MH⁺), RT = 1.70, purity: 80%.

30 2-[2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl]-4-methoxynicotinonitrile: 2av: LC/MS (m/z) 414 (MH⁺), RT = 1.8, purity: 83%.

6-Chloro-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2ax: LC/MS (m/z) 436 (MH⁺), RT = 2.0, purity: 86%.

6-Chloro-2-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2ay: LC/MS (m/z) 461 (MH⁺), RT = 2.0, purity: 84%.

5 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-ethylpyrimidine, 2az: LC/MS (m/z) 387 (MH⁺), RT = 1.8, purity: 83%.

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-trifluoromethylpyrimidine, 2ba: LC/MS (m/z) 427 (MH⁺), RT = 1.8, purity: 78%.

10 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethoxypyrimidine, 2bb: LC/MS (m/z) 420 (MH⁺), RT = 1.9, purity: 70%.

4-Chloro-2-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylpyrimidine, 2bc: LC/MS (m/z) 433 (MH⁺), RT = 1.8, purity: 78%.

15 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-trifluoromethylpyrimidine, 2bd: LC/MS (m/z) 434 (MH⁺), RT = 2.0, purity: 84%.

20 Pharmacological testing

The affinity of the compounds of the invention to 5-HT_{1A} receptors was determined by measuring the inhibition of binding of a radioactive ligand at 5-HT_{1A} receptors as described in the following test:

25

Inhibition of ³H-5-CT Binding to Human 5-HT_{1A} Receptors.

By this method the inhibition by drugs of the binding of the 5-HT_{1A} agonist ³H-5-carboxamido tryptamine (³H-5-CT) to cloned human 5-HT_{1A} receptors stably expressed in transfected HeLa cells (HA7) (Fargin, A. et al. *J. Biol. Chem.* 1989, 264, 14848) is determined *in vitro*. The assay was performed as a modification of the method described by Harrington, M.A. et al. *J. Pharmacol. Exp. Ther.* 1994, 268, 1098. Human 5-HT_{1A} receptors (40 µg of cell homogenate) were incubated for 15 minutes at 37 °C in 50

mM Tris buffer at pH 7.7 in the presence of ^3H -5-CT. Non-specific binding was determined by including 10 μM of metergoline. The reaction was terminated by rapid filtration through Unifilter GF/B filters on a Tomtec Cell Harvester. Filters were counted in a Packard Top Counter. Compounds 1a, 1b, 2a, 2c, 2l, 2o, 2s, 2u, 2z, 2aa, 2ah, 2ai and 2aj were tested and 5 showed IC₅₀ values of less than 300 nM.

The compounds of the invention have also been tested for their effect on re-uptake of serotonin in the following test:

10 **Inhibition of ^3H -5-HT Uptake Into Rat Brain Synaptosomes.**

Using this method, the ability of drugs to inhibit the accumulation of ^3H -5-HT into whole rat brain synaptosomes is determined *in vitro*. The assay was performed as described by Hyttel, J. *Psychopharmacology* 1978, 60, 13. Compounds 1a, 1r, 2a, 2c, 2l, 2o, 2s, 2u, 2z, 15 2aa, 2ah, 2ai and 2aj were tested and showed IC₅₀ values of less than 20 nM.

The 5-HT_{1A} antagonistic activity of some of the compounds of the invention has been estimated *in vitro* at cloned 5-HT_{1A} receptors stably expressed in transfected HeLa cells (HA7). In this test, 5-HT_{1A} antagonistic activity is estimated by measuring the ability of the 20 compounds to antagonize the 5-HT induced inhibition of forskolin induced cAMP accumulation. The assay was performed as a modification of the method described by Pauwels, P.J. et al. *Biochem. Pharmacol.* 1993, 45, 375. Compounds 1a, 1b, 1e and 1v were tested and showed IC₅₀ values of less than 7000 nM.

25 Some of the compounds of the invention have also been tested for their *in vivo* effect on 5-HT_{1A} receptors in the assay described by Sánchez. C. et al. *Eur. J. Pharmacol.* 1996, 315, pp 245. In this test, antagonistic effects of test compounds are determined by measuring the ability of the test compounds to inhibit 5-MeO-DMT induced 5-HT syndrome.

30 The compounds of the present invention possess valuable activity as serotonin re-uptake inhibitors and have antagonistic effect at 5-HT_{1A} receptors. The compounds of the invention are therefore considered useful for the treatment of diseases and disorders responsive to the inhibition of serotonin re-uptake and antagonistic activity at 5-HT_{1A} receptors. Diseases

responsive to the inhibition of serotonin re-uptake are well-known in the art and include affective disorders, such as depression, psychosis, anxiety disorders including general anxiety disorder, panic disorder, obsessive compulsive disorder, etc.

- 5 As explained above, the antagonistic activity at 5-HT_{1A} receptors of the compounds of the invention will counteract the negative feed back mechanism induced by the inhibition of serotonin reuptake and is thereby expected to improve the effect of the serotonin reuptake inhibiting activity of the compounds of the invention.
- 10 The compounds as claimed herein are therefore considered to be particularly useful as fast onset of action medicaments for the treatment of depression. The compounds may also be useful for the treatment of depressions which are non-responsive to currently available SSRIs.

15

Some of the compounds of the invention have also been found to have affinity to dopamine D₃ and D₄ receptors in the following two assays.

- 20 **Inhibition of the binding of ³H-YM-09151-2 to human dopamine D₄ receptors**

By this method, the inhibition by drugs of the binding of [³H]YM-09151-2 (0.06 nM) to membranes of human cloned dopamine D_{4,2}-receptors expressed in CHO-cells is determined *in vitro*. Method modified from NEN Life Science Products, Inc., technical data certificate 25 PC2533-10/96.

Inhibition of the binding of ³H]-Spiperone to human D₃ receptors

By this method, the inhibition by drugs of the binding [³H]Spiperone (0.3 nM) to membranes of human cloned dopamine D₃-receptors expressed in CHO-cells is determined *in vitro*. Method modified from R.G. MacKenzie et al. *Eur. J. Pharm.-Mol. Pharm. Sec.* 1994, 266, 79-85.

As seen from the above, the compounds of the invention show affinity for the 5-HT_{1A} receptors, inhibitory activity at serotonin reuptake sites, and affinity for dopamine D₃ and D₄ receptors. Accordingly, the compounds are considered useful for the treatment of psychiatric and neurological disorders as mentioned previously.

5

Pharmaceutical formulation


The pharmaceutical formulations of the invention may be prepared by conventional methods in the art. For example: Tablets may be prepared by mixing the active ingredient with 10 ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.

15 Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilising the solution and filling it in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.

20 The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions, methods well-known in the art 25 may be used, and any pharmaceutically acceptable carriers, diluents, excipients or other additives normally used in the art may be used.

Conveniently, the compounds of the invention are administered in unit dosage form containing said compounds in an amount of about 0.01 to 1000 mg. The total daily dose is 30 usually in the range of about 0.05 - 500 mg, and most preferably about 0.1 to 50 mg of the active compound of the invention.

Claims



5

(I)

wherein

X represents O, NR¹⁶, S or CR⁴R⁵.10 Y is -CR⁶R⁷-, -CR⁶R⁷-CR⁸R⁹-, -CR⁶=CR⁷- or CO-CR⁶R⁷; orX and Y together form a group -CR⁴=CR⁵- or -CR⁴=CR⁵-CR⁶R⁷;

Z represents O or S;

n is 2, 3, 4, 5, 6, 7, 8, 9 or 10;

15 m is 2 or 3;

A is O or S;

W is N, C or CH;

Q is N, C or CH;

wherein the dotted line means an optional bond;

20

R¹ - R⁹ are each independently selected from hydrogen, halogen, nitro, cyano, trifluoromethyl, trifluoromethoxy, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, aryl-C₁₋₆-alkyl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, hydroxy, formyl, acyl, amino, C₁₋₆-alkylamino, di(C₁₋₆-alkyl)amino, acylamino, C₁₋₆-alkoxycarbonylamino, aminocarbonylamino, C₁₋₆-alkylaminocarbonylamino and di(C₁₋₆-alkyl)aminocarbonylamino; and

25

R¹⁶ is selected from hydrogen, halogen, nitro, cyano, trifluoromethyl, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, aryl-C₁₋₆-alkyl, formyl,

acyl; and R¹⁰ and R¹¹ are each independently selected from hydrogen and C₁₋₆-alkyl or may together form a bridge consisting of two or three methylene groups; and

R¹², R¹³, R¹⁴ and R¹⁵ are each independently selected from hydrogen, halogen, nitro, cyano, 5 trifluoromethyl, trifluoromethoxy, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₂₋₆-alkynyl, C₃₋₈-cycloalkyl, C₃₋₈-cycloalkyl-C₁₋₆-alkyl, aryl, heteroaryl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, C₁₋₆-alkylsulphonyl, hydroxy, formyl, acyl, amino, acylamino, aminocarbonyl, C₁₋₆-alkoxycarbonylamino, aminocarbonylamino, C₁₋₆-alkylaminocarbonylamino, di(C₁₋₆-alkyl)aminocarbonylamino, SO₂NR²⁰R²¹ and NR²⁰R²¹ wherein R²⁰ and R²¹ independently represent hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl or phenyl; or R²⁰ and R²¹ together with the nitrogen to which they are 10 attached form a 5- or 6-membered ring optionally containing one further heteroatom, which ring may optionally be substituted by C₁₋₆-alkyl or acyl;

any of its enantiomers or any mixture thereof, or an acid addition salt thereof.

15

2. A compound of Claim 1, characterised in that Z is -O-.

3. A compound of Claim 1, characterised in that Y is -CR⁶R⁷ or Y is -CH₂CO-.

20

4. A compound of Claim 1, characterised in that X is O or NH.

5. A compound of any of the Claims 1 - 4, characterised in that W is N.

6. A compound of any of the Claims 1 - 5, characterised in that n is 2, 3 or 4.

25

7. A compound of Claim 6, characterised in that n is 2.

8. A compound of any of the Claim 1 - 7, characterised in that R¹, R² and R³ are independently representing hydrogen, halogen or CN.

30

9. A compound of any of the Claims 1-8, characterised in that R¹², R¹³, R¹⁴ and R¹⁵ are independently selected from the group consisting of hydrogen, halogen, C₁₋₆-alkyl, C₂₋₆-alkenyl, C₁₋₆-alkoxy, cyano, C₁₋₆-alkylsulphonyl, acyl, nitro, trifluoromethyl and trifluoromethoxy.

10. A compound of any of the Claims 1 - 8, characterised in that R^{12} , R^{13} , R^{14} and R^{15} are independently selected from a group consisting of hydrogen, heteroaryl, trifluoromethyl, cyano, C_{1-6} -alkyl, C_{3-8} -cycloalkyl, halogen, $NR^{20}R^{21}$, $SO_2NR^{20}R^{21}$, aryl, C_{1-6} -alkylsulfonyl aminocarbonyl and acylamino.

5

11. A compound of Claim 10, characterised in that R^{12} , R^{13} , R^{14} and R^{15} are independently selected from the group consisting of hydrogen, thiophen, trifluoromethyl, cyano, methyl, ethyl, cyclopropyl, chloro, bromo, fluoro, piperazinyl, 1-piperidinyl, 1-piperidinyl-sulfonyl, methanesulfonyl, methylsulfidyl, phenyl aminocarbonyl and acylamino.

10

12. The compound according to claim 1 which is

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinonitrile, 1a

15 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methyl-4-trifluoromethylnicotinonitrile, 1b

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methyl-4-trifluoromethylnicotinonitrile, 1c

20 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-(thiophen-2-yl)-4-trifluoromethylnicotinonitrile, 1d

{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinonitrile, 1e

3-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-2-methylpyridine, 1f

2-Chloro-3-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1g

25 2-Bromo-3-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1h

3-Chloro-5-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1i

2-Chloro-3-{2-[4-(8-cyano-2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1j

2-Bromo-3-{2-[4-(8-Cyano-2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-

30 yl]ethoxy}pyridine, 1k

3-Chloro-5-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 1l

3-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-2-methylpyridine, 1m

4-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-(piperidin-1-ylsulfonyl)pyridine, 1n

5 4-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-(piperidin-1-ylsulfonyl)pyridine, 1o

2-{4-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, 1p

2-{4-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine 1q

10 2-{4-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-5-trifluoromethylpyridine, 1r

2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-5-trifluoromethylpyridine, 1s

15 2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-4,6-dimethylnicotinonitrile, 1t

2-{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]butylsulfanyl}-4,6-dimethylnicotinonitrile, 1u

2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-5-trifluoromethylpyridine, 1v

20 2-{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propylsulfanyl}-4,6-dimethylnicotinonitrile, 1x

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2a

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-3-methanesulfonyl-4-methyl-6-phenylpyridine, 2b

2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methyl-6-(piperidin-1-yl)nicotinonitrile, 2c

2-{2-[4-(8-Cyano-2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylnicotinamide, 2d

25 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2e

30 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2f

4-Cyano-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}pyridine, 2f

2-<{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-6-methylnicotinamide,
2g

2-<{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy)-4-methyl-6-(piperidin-1-
yl)nicotinonitrile, 2h

5 2-<{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy)-4-methyl-6-(4-
methylpiperazin-1-yl)nicotinonitrile, 2i

6-Cyclopropyl-2-<{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy)-4-
trifluoromethylnicotinonitrile, 2j

2-<{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethoxy}-3-methanesulfonyl-4-
10 methyl-6-phenylpyridine, 2k

2-<{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethyl-3-
phenylsulfonylpyridine, 2l

2-<{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyridine,
2m

15 2-<{3-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-
dimethylnicotinonitrile, 2n

6-Chloro-2-<{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-
methylnicotinonitrile, 2o

5-Chloro-2-<{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-
20 yl]ethylsulfanyl}nicotinonitrile, 2p

6-Chloro-2-<{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-
yl]ethylsulfanyl}nicotinonitrile, 2q

6-Chloro-2-<{3-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-
fluoronicotinonitrile, 2r

25 2-<{3-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-
dimethylnicotinonitrile, 2s

6-Chloro-2-<{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-
4-methylnicotinonitrile, 2t

5-Chloro-2-<{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-
30 4,6-dimethylnicotinonitrile, 2u

5-Chloro-2-<{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-
yl]ethylsulfanyl}nicotinonitrile, 2v

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}nicotinonitrile, 2x

6-Chloro-2-{3-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2y

5 2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2z

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2aa

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4-methylnicotinonitrile, 2ab

10 4-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, 2ac

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2ad

15 5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2ae

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2af

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-3-on-8-yl)piperazin-1-yl]ethylsulfanyl]-5-fluoronicotinonitrile, 2ag

20 2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2ah

2-[2-[4-(6-Chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4,6-dimethylnicotinonitrile, 2ai

25 6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-4-methylnicotinonitrile, 2aj

4-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-6-methylnicotinonitrile, 2ak

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-

30 4,6-dimethylnicotinonitrile, 2al

5-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2am

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]nicotinonitrile, 2an

6-Chloro-2-[2-[4-(6-chloro-2,3-dihydro-1,4-benzoxazin-8-yl)piperazin-1-yl]ethylsulfanyl]-5-fluoronicotinonitrile, 2ao

5 5-Cyano-4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyrimidine, 2ap

5-Cyano-4-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylsulfanyl-2-phenylpyrimidine, 2aq

5-Cyano-4-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}pyrimidine, 2ar

10 5-Cyano-4-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylsulfanyl-2-phenylpyrimidine, 2as

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylpyrimidine, 2at

15 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethylpyrimidine, 2au

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-methoxynicotinonitrile, 2av

6-Chloro-2-{2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2ax

20 6-Chloro-2-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-fluoronicotinonitrile, 2ay

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-5-ethylpyrimidine, 2az

25 2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-trifluoromethylpyrimidine, 2ba

2-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4,6-dimethoxypyrimidine, 2bb

4-Chloro-2-{2-[4-(8-cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-6-methylpyrimidine, 2bc

30 2-{2-[4-(8-Cyano-2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethylsulfanyl}-4-trifluoromethylpyrimidine, 2bd

or an acid addition salt thereof.

13. A pharmaceutical composition comprising at least one compound of Formula I according to claims 1-12, or a pharmaceutically acceptable acid addition salt thereof or 5 prodrug thereof in a therapeutically effective amount and in combination with one or more pharmaceutically acceptable carriers or diluents.
14. The use of a compound according to claims 1 to 12 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of a disorder 10 or disease responsive to the combined effect of 5-HT_{1A} receptors and dopamine D₄ receptors.
15. The use of a compound according to claims 1 to 12 or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for the treatment of a disorder 15 or disease responsive to the combined effect of inhibition of serotonin uptake and antagonism of 5-HT_{1A} receptors.
16. The use of a compound according to any of the claims 14 to 15 wherein the medicament is for the treatment of affective disorders such as general anxiety disorder, 20 panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and neurological disorders such as psychosis.
17. A method for the treatment of a disorder or disease of living animal body, including a human, which is responsive to the effect of inhibition of serotonin uptake and antagonism 25 of 5-HT_{1A} receptors comprising administering to such a living animal body, including a human, a therapeutically effective amount of a compound according to claims 1 to 12 or a pharmaceutically acceptable acid addition salt thereof.
18. A method for the treatment of a disorder or disease of living animal body, including 30 a human, which is responsive to the effect of 5-HT_{1A} and D₄ receptors comprising administering to such a living animal body, including a human, a therapeutically effective amount of a compound according to claims 1 to 12 or a pharmaceutically acceptable acid addition salt thereof.

19. A method of treatment according to claim 17 to 18 where the disorder or disease is an affective disorder such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, or a neurological disorder such as
5 psychosis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 02/00435

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 405/12, C07D 413/12, A61K 31/497, A61K 31/536
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. Med. Chem., Volume 37, 1994, Bart J. van Steen et al: "Structure-Affinity Relationship Studies on 5-HT1A Receptor Ligands. 2. Heterobicyclic Phenylpiperazines with N4-Aralkyl Substituents", pages 2761-2773 -----	1-16

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 October 2002

Date of mailing of the international search report

09-10-2002

Name and mailing address of the ISA/
 Swedish Patent Office
 Box 5055, S-102 42 STOCKHOLM
 Facsimile No. + 46 8 666 02 86

Authorized officer

GÖRAN KARLSSON/BS
 Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/DK02/00435**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos. **17-19**
because they relate to subject matter not required to be searched by this Authority, namely:
**A method for treatment of the human or animal body by therapy,
see rule 39.1**
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.